Sichuan Kelun Pharmaceutical Co Ltd (002422) - Total Assets
Based on the latest financial reports, Sichuan Kelun Pharmaceutical Co Ltd (002422) holds total assets worth CN¥41.14 Billion CNY (≈ $6.02 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Sichuan Kelun Pharmaceutical Co Ltd (002422) long-term investment share to see how much of total assets are deployed in long-term investments.
Sichuan Kelun Pharmaceutical Co Ltd - Total Assets Trend (2007–2025)
This chart illustrates how Sichuan Kelun Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Sichuan Kelun Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Sichuan Kelun Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Sichuan Kelun Pharmaceutical Co Ltd's total assets of CN¥41.14 Billion consist of 50.3% current assets and 49.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.1% |
| Accounts Receivable | CN¥4.67 Billion | 11.7% |
| Inventory | CN¥3.85 Billion | 9.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.23 Billion | 3.1% |
| Goodwill | CN¥96.25 Million | 0.2% |
Asset Composition Trend (2007–2025)
This chart illustrates how Sichuan Kelun Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Sichuan Kelun Pharmaceutical Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sichuan Kelun Pharmaceutical Co Ltd's current assets represent 50.3% of total assets in 2025, a decrease from 61.8% in 2007.
- Cash Position: Cash and equivalents constituted 15.1% of total assets in 2025, up from 5.8% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 4.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 11.7% of total assets.
Sichuan Kelun Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Sichuan Kelun Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX114.07 Billion |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357
|
China | CN¥2.89 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Sichuan Kelun Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.11 | 2.03 | 1.10 |
| Quick Ratio | 1.74 | 1.61 | 0.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥11.22 Billion | CN¥9.40 Billion | CN¥1.31 Billion |
Sichuan Kelun Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sichuan Kelun Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.17 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 6.7% |
| Total Assets | CN¥39.83 Billion |
| Market Capitalization | $8.31 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sichuan Kelun Pharmaceutical Co Ltd's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sichuan Kelun Pharmaceutical Co Ltd's assets grew by 6.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sichuan Kelun Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual total assets of Sichuan Kelun Pharmaceutical Co Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥39.83 Billion ≈ $5.83 Billion |
+6.75% |
| 2024-12-31 | CN¥37.32 Billion ≈ $5.46 Billion |
+2.36% |
| 2023-12-31 | CN¥36.45 Billion ≈ $5.33 Billion |
+6.57% |
| 2022-12-31 | CN¥34.21 Billion ≈ $5.01 Billion |
+8.45% |
| 2021-12-31 | CN¥31.54 Billion ≈ $4.62 Billion |
-1.47% |
| 2020-12-31 | CN¥32.01 Billion ≈ $4.68 Billion |
+1.67% |
| 2019-12-31 | CN¥31.49 Billion ≈ $4.61 Billion |
+7.30% |
| 2018-12-31 | CN¥29.34 Billion ≈ $4.29 Billion |
+4.85% |
| 2017-12-31 | CN¥27.99 Billion ≈ $4.10 Billion |
+19.56% |
| 2016-12-31 | CN¥23.41 Billion ≈ $3.43 Billion |
+3.66% |
| 2015-12-31 | CN¥22.58 Billion ≈ $3.30 Billion |
+6.51% |
| 2014-12-31 | CN¥21.20 Billion ≈ $3.10 Billion |
+18.14% |
| 2013-12-31 | CN¥17.95 Billion ≈ $2.63 Billion |
+20.20% |
| 2012-12-31 | CN¥14.93 Billion ≈ $2.18 Billion |
+42.67% |
| 2011-12-31 | CN¥10.47 Billion ≈ $1.53 Billion |
+18.63% |
| 2010-12-31 | CN¥8.82 Billion ≈ $1.29 Billion |
+164.65% |
| 2009-12-31 | CN¥3.33 Billion ≈ $487.78 Million |
+25.50% |
| 2008-12-31 | CN¥2.66 Billion ≈ $388.68 Million |
+48.62% |
| 2007-12-31 | CN¥1.79 Billion ≈ $261.53 Million |
-- |
About Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, ve… Read more